Panostaja Oyj
17.3.2021 15:47:24 CET | Globenewswire | Press release
Panostaja Oyj Managers' Transactions
Panostaja Oyj Stock Exchange Bulletin, Managers´ Transactions March 17, 2021 at 16:45 pm.
| Person subject to the notification requirement | ||
| Name: | Treindex Oy Mikko Koskenkorva | Legal Person |
| Position: | Member of the Board/Deputy member | |
| Initial Notification | ||
| Reference number: | 743700ZGH7GD27UOQO12_20210317143901_37 | |
| Issuer | ||
| Name: | Panostaja Oyj | |
| LEI: | 743700ZGH7GD27UOQO12 | |
| Transaction details | ||
| Transaction date: | 2021-03-17 | |
| Venue: | NASDAQ HELSINKI LTD (XHEL) | |
| Nature of the transaction: | Disposal | |
| Instrument: | Share | |
| ISIN: | FI0009800379 | |
| Volume: | 480000 | |
| Unit price: | 0,70400 Euro | |
| Aggregated transactions | ||
| Volume: | 480000 | |
| Volume weighted average price: | 0.70400 Euro | |
PANOSTAJA OYJ
For further information, contact CEO Tapio Tommila: tel. +358 (0)40-527 6311
www.panostaja.fi/en/
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sanofi Winthrop Industrie18.4.2026 12:00:00 CEST | Press release
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
Organizing Committee of the 2026 Fujian Provincial Conference on the Development of Cultural and Tourism Economy18.4.2026 06:50:27 CEST | Press release
2026 Fujian Provincial Conference on Development of Cultural, Tourism Economy opens on Apr. 17 in Zhangzhou, SE China's Fujian
Evaxion17.4.2026 21:10:00 CEST | Press release
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
Zymeworks Inc.17.4.2026 21:00:00 CEST | Press release
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Evaxion17.4.2026 21:00:00 CEST | Press release
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom